Ekuba

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ekuba

Property Description
Active ingredient Chlorhexidine Gluconate
Form Liquid, Oral Rinse, Gel, Solution
Pharmacological class Antiseptic and Germicide
Common use General hygiene and microbial control
Origin Synthetic chemical compound

What Type of Medicine is Ekuba? Defining the Chemical and Pharmacological Class

Ekuba is a commercial trade name for a medicine containing the active substance Chlorhexidine Gluconate, which is utilized for its utility as an Antiseptic and a Germicide. This agent is a synthetic chemical entity belonging to the bisbiguanide class. As a Topical Antimicrobial, its intended role is the destruction or inhibition of microorganisms directly on surfaces like the skin or oral mucosa, a classification that distinguishes it from antibiotics designed for internal, systemic action.

Composition and Physical Forms of Chlorhexidine Gluconate

The pharmaceutical identity of Ekuba is defined by its core component, the single active ingredient, Chlorhexidine Gluconate, which is presented in various forms for the Topical Application Route. These forms, including Aqueous Solutions, Liquids used as an Oral Rinse or Mouthwash, and Gels, utilize an aqueous or hydroalcoholic base/vehicle to facilitate delivery. The compound's chemical property as a cationic substance allows for binding capability to tissue, a feature for providing sustained presence in the targeted area.

What is the General Purpose of Ekuba?

The general purpose of this medicine is to support hygiene and manage localized microbial levels, such as those associated with routine dental care or minor skin procedures. Its antimicrobial action involves functioning as a broad-spectrum biocide, capable of affecting a wide range of bacteria and fungi. A key differentiating factor is its substantivity, a property where the active antimicrobial agent binds to tissues and maintains a continuous effect over an extended duration, a mechanism utilized for long-lasting hygienic management.

Regulatory References

  1. DrugBank Online

What side effects are possible with Ekuba?

Possible Side Effects and Safety Information

The official regulatory safety documents for Chlorhexidine Gluconate (Ekuba) categorize adverse reactions into local effects, which are frequent and generally transient, and rare but serious systemic reactions.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the standard regulatory frequency framework:

  • Common: The most frequently documented effects are related to the application site, including transient taste disturbance and a burning sensation of the tongue. These effects are documented to often diminish with continued use.
  • Uncommon: This category includes superficial discolouration of the dorsum of the tongue. Staining of the teeth and other oral surfaces is also a well-documented effect that is noted as being reversible upon discontinuing the medicine.
  • Very Rare: Severe systemic hypersensitivity reactions are documented, including anaphylaxis, angioedema (swelling beneath the skin), and urticaria (hives).

Serious Safety Characteristics

Immune System Disorders include the very rare occurrence of anaphylactic reactions. This serious, systemic response forms the basis for the primary safety restriction: the medicine is formally contraindicated in patients with a known history of hypersensitivity to chlorhexidine or any other component in the formulation.

Population-Specific Safety Notes

The official safety profile includes explicit constraints regarding topical use in specific vulnerable groups. A documented risk of chemical skin burns exists when this antiseptic is used topically in neonates and preterm infants, particularly those born before 32 weeks of gestation.

The overall safety profile is structured by the strict formal boundary of the contraindication against hypersensitivity, while addressing the management of common, reversible local effects.

Overdose and Emergency Response

The official regulatory profile for Ekuba (Chlorhexidine Gluconate) identifies two distinct situations requiring emergency medical attention: significant accidental ingestion and severe systemic reactions.

Overdose from swallowing standard, low-concentration oral rinse is generally documented as having an unlikely potential for systemic effects due to the active ingredient's poor oral absorption. However, ingestion of large volumes or highly concentrated solutions is associated with localized gastrointestinal mucosa irritation or gastritis. More severe systemic toxicity, including blood disorders and certain neurological effects like toxic leukoencephalopathy, may occur following ingestion of high concentrations.

Immediate medical attention is required for any signs of a serious allergic reaction (hypersensitivity). Regulatory guidance from authorities such as the FDA states that symptoms of this potentially life-threatening event, known as anaphylaxis, may occur within minutes of exposure. These symptoms include wheezing or difficulty breathing, swelling of the face, hives, or the development of shock or hypotension.

If accidental ingestion occurs, medical advice must be sought. Officially described management procedures may include supportive measures and, where appropriate, gastric lavage. In cases of severe systemic reaction, immediate respiratory and/or cardiovascular support is required to manage the potential for circulatory collapse.

Therapeutic Uses of Ekuba

Ekuba, containing the antiseptic Chlorhexidine Gluconate, is generally used to provide supportive symptom management and microbial control. It is primarily relevant in conditions involving inflammatory or irritative processes caused by localized microbial activity.

Relief from Plaque-Induced Gum Symptoms

This domain covers the common oral application of Ekuba, which is relevant for managing the symptom cluster of gingivitis—characterized by redness, swelling, and bleeding of the gums. This medicine is utilized in conditions involving these inflammatory or irritative processes. The key benefit is sustained plaque control, which may support gum tissue integrity and contributes to managing the overall symptom load during periods of heightened symptoms.

This medicine is commonly used across conditions presenting with acute or episodic manifestations, including symptomatic gingivitis and situations requiring temporary supportive management of microbial risk after oral procedures.

“This medicine is relevant when supportive symptom management is appropriate, particularly in contexts involving heightened systemic burden due to microbial contamination risk.”

Supportive Care in Specialized Contexts

Ekuba is applied in situations that create temporary functional strain, such as immediately following invasive dental work, or as a broad-spectrum topical solution for microbial reduction on the skin surface. The primary benefit is applied in addressing the risk of microbial contamination at the healing site, which may assist with coping with symptom fluctuations.


Quick Fact: Relief for Inflammatory Symptoms Ekuba is applied in addressing groups of symptoms that may become disruptive, particularly those related to inflammatory or irritative states.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for Ekuba, which contains Chlorhexidine Gluconate, is strictly defined by regulatory documentation concerning specific population groups and application contexts.

Contraindications and Absolute Prohibitions

Use of Ekuba is absolutely contraindicated for any person with a known history of hypersensitivity or allergy to Chlorhexidine Gluconate or any other component in the product formulation. Furthermore, specific topical forms are prohibited from internal contact with the meninges, middle ear, or in procedures like a lumbar puncture.

Age-Group Eligibility

The safety and effectiveness of the oral rinse formulation have not been established for children under the age of 18. Certain topical solutions are not recommended for use in children younger than 2 months of age due to the potential risk of increased systemic absorption and irritation.

Pregnancy and Lactation

For pregnant women, the oral rinse (FDA Pregnancy Category B) should be used only if clearly needed due to a lack of adequate human studies. Caution should be exercised when administering the medicine to nursing women.

What should I know about interactions with other medicines?

The official interaction profile for Ekuba, which contains Chlorhexidine Gluconate, is defined by the absence of systemic pharmacokinetic interactions. Due to the minimal absorption of the active ingredient from the oral rinse or topical application routes, regulatory bodies have not documented interactions mediated by metabolic enzymes or drug transporters that would alter the plasma exposure of co-administered medicines.

Documented Local Antagonism

The primary documented interaction concern is a local physical incompatibility. The cationic active ingredient is chemically antagonized by anionic agents, which are commonly included in conventional oral hygiene products, specifically dentifrice (toothpaste). Co-administration with these anionic substances causes a physical neutralization, resulting in a reduction of the local antimicrobial efficacy.

Administration Separation Requirements

To prevent this loss of local effect, regulatory labeling enforces mandatory administration timing separation rules:

  • Anionic Agents: Products containing anionic agents must be used separately, and the oral cavity should be thoroughly rinsed with water before Ekuba administration, or the products must be used at different times of the day.
  • Post-Administration Restrictions: To maintain the necessary therapeutic concentration of the product, official instructions state that users must not rinse the mouth with water or other mouthwashes immediately following use. Consumption of food or beverages should also be avoided immediately after administration.

No population-specific interaction cautions or increased interaction severity for defined patient populations are noted in official regulatory documentation.

Mechanism of Action

How Ekuba Works: Mechanism of Action


Membrane Disruption and Cellular Lysis

The core mechanism involves the positively charged active component's strong cationic binding to the negatively charged microbial cell envelope, including the cytoplasmic membrane. This forceful electrostatic attraction immediately disrupts the cell's barrier function, leading to the rapid leakage of vital intracellular components and initiating the anti-microbial cascade.


Intracellular Coagulation and Metabolic Shutdown

Following membrane damage, the agent penetrates the microbial interior where it interacts with and precipitates key macromolecules such as proteins and nucleic acids. This structural destruction and subsequent metabolic shutdown transition the action from bacteriostatic to a definitive bactericidal effect, resulting in the irreversible cessation of microbial function.


️ Tissue Adsorption for Sustained Activity (Substantivity)

The mechanism includes strong adsorption of the active component to the anionic sites on host tissues (skin and mucosa), forming a persistent surface reservoir. This substantivity mechanism mediates the slow, continuous release of the anti-microbial agent, prolonging the physiochemical anti-microbial activity on the application surface.

Dosage and Administration Information

Administration Scope: Usage Guidelines

Ekuba, containing Chlorhexidine Gluconate, is administered through various forms and routes, each with instructions detailing its use. The primary forms are the 0.12% Oral Rinse, the 4% Topical Solution, and the 2.5 mg Periodontal Chip.

Feature Description of Use
Route of administration Oral Rinse: Topical application to the oral mucosa; it is not intended for ingestion (swallowing). Periodontal Chip: Subgingival insertion into the gum pocket by a dental professional. Topical Solution: External application to the skin for cleansing or scrubbing.
Dosing schedule Oral Rinse: The dose is 15 mL of the undiluted 0.12% solution. Periodontal Chip: One 2.5 mg chip is inserted per affected pocket greater than or equal to 5 mm, with a maximum of eight chips per visit.
Frequency and timing Oral Rinse: Twice daily (morning and evening). The solution must be swished for 30 seconds before expectoration. Periodontal Chip: Treatment is administered once, with re-treatment recommended at intervals of three months or longer for persistent pockets.
Preparation requirements Oral Rinse: Use is initiated immediately following a professional dental prophylaxis (cleaning). Periodontal Chip: The insertion site must be isolated and dried by the healthcare provider.
Age-group administration rules Clinical effectiveness of the Oral Rinse has not been established in patients under 18 years of age. The Topical Solution requires care in infants under 2 months of age.
Special procedural conditions Oral Rinse: Patients must not rinse with water, brush, or eat immediately after using the solution. Periodontal Chip: Patients must avoid dental floss at the treated site for 10 days post-insertion.

Connection to the overall use protocol:

These instructions establish a procedural and localized use protocol, defining numerical doses and time constraints for the duration of contact with the active agent. The administration method is topical, and constraints such as post-rinse fasting and the need for prior professional cleaning are components of the usage pattern.

Recent Clinical Evidence

Research evidence / Overview of studies for Ekuba

Evidence for Use in Plaque-Induced Gingivitis (Oral Rinse)

Research has explored outcomes related to plaque-induced gum inflammation, a condition characterized by redness, swelling, and bleeding of the gums. The primary evidence base comes from many short-term and medium-term Randomized Controlled Trials (RCTs) and larger Systematic Reviews. Researchers primarily monitored changes in objective clinical measures, such as Plaque Accumulation and indices that track the severity of Gum Inflammation and Bleeding.

Studies reported differences in measurements of plaque levels and indicators of gum inflammation recorded between the active product group and control groups. Meta-analyses reported that the use of the rinse was associated with differences in recorded bleeding scores when assessed by clinicians. This research provides insight into short-term changes in outcomes linked to inflammatory or irritative states.

Evidence for Use in Surgical Site Microbial Reduction (Topical/Skin Preparation)

Ekuba has been evaluated in research exploring its role as an antiseptic preparation on the skin surface prior to various surgical procedures. The evidence largely comes from large-scale Randomized Controlled Trials and Meta-analyses. These studies primarily focused on two types of outcomes: the immediate reduction in bacterial counts on the skin surface (microbial bioburden) and the subsequent rate of Surgical Site Infections (SSIs), particularly those affecting the skin surface.

The data show patterns related to microbial bioburden, where the application was followed by an observed reduction in bacterial counts over a defined time interval at the site. Studies that monitored the incidence of superficial SSIs reported differences in the rates recorded between the active preparation and control groups. Research exploring more serious infections has shown mixed findings, and patterns were less uniform across all types of surgical procedures examined.

What Research Remains Unclear or Inconsistent

The research provides context but also highlights areas where certainty remains low. Evidence quality varies across studies, particularly when results are combined in large analyses. For gingivitis, the follow-up durations were limited, leaving open questions about long-term maintenance. Subgroup findings are uncertain for patients with higher risk factors. Finally, comparative evidence is lacking against other non-placebo active products in some areas, meaning that while studies compared Ekuba to control or placebo, head-to-head research against all other treatments is not comprehensive.

Key Studies & References

  1. NICE Guideline: Surgical site infections: prevention and treatment
  2. Meta-analysis of chlorhexidine mouthwash use after dental extraction

Frequently Asked Questions (FAQ)

Common questions about Ekuba (FAQ)


Q: Can Ekuba be taken with food?

Official instructions for the oral rinse formulation state that consumption of food or beverages should be avoided for at least 30 minutes after using the product. This separation helps ensure the active ingredient binds effectively to the oral tissues for its local anti-microbial effect.


Q: Are there any common over-the-counter medicines that interact with Ekuba?

Regulatory information indicates that due to the minimal absorption of Ekuba into the bloodstream, it is not generally known to cause problems when used alongside common over-the-counter medicines. The primary documented concern is a local physical incompatibility with anionic agents, which are often found in toothpastes. This local interaction can reduce the drug's activity at the application site.


Q: Does Ekuba require any special monitoring by a doctor?

The official product labeling does not require routine systemic monitoring, such as blood tests, because very little of the drug is absorbed into the body. However, the oral rinse form is administered following a professional dental cleaning, as described in the use instructions. Healthcare providers may also recommend follow-up cleanings to address potential staining.


Q: Can I take pain relievers while using Ekuba?

Since Ekuba is minimally absorbed systemically, official drug information indicates that it is not expected to interfere with systemic medications like pain relievers. The known interaction is restricted to local issues with certain oral hygiene products.


Q: Can I use Ekuba if I am already taking an antidepressant?

Official drug information emphasizes that Ekuba has no documented systemic pharmacokinetic interactions because the active component is minimally absorbed after oral or topical use. This means it is highly unlikely to affect the way systemic medications like antidepressants are processed.


Q: Can pregnant people use Ekuba?

Official regulatory documents classify the oral rinse based on available data. Use during pregnancy is recommended only when clearly needed, due to a lack of adequate human studies and a need for a healthcare provider to assess necessity.


Q: Can I take alcohol while on Ekuba?

Some oral rinse formulations of Ekuba contain alcohol. While the drug label does not give specific instructions against the consumption of alcoholic beverages by adults, accidental ingestion of a large volume of the rinse can lead to symptoms of alcohol intoxication, particularly in small children.


Q: Can Ekuba cause weight changes?

Weight change is not listed in the official regulatory safety documents as a known common, uncommon, or rare side effect of Ekuba. The documented adverse reactions are primarily related to local effects at the site of application, such as taste changes or staining.


Q: How long does the effect of one dose of Ekuba usually last?

Ekuba works via a property called 'substantivity,' meaning the active ingredient strongly binds to the applied tissue and is released slowly. For the oral rinse, studies indicate this sustained anti-microbial activity can last for up to 12 hours. This sustained activity aligns with the recommended interval between applications.


Q: Is Ekuba used for any conditions other than the main one listed?

Ekuba is a broad-spectrum antiseptic and germicide. While the official labeling focuses on plaque-induced gingivitis and pre-surgical skin preparation, the topical solution is also known for general use in skin cleansing and hand scrubbing.


Q: Is Ekuba the same as other treatments for this condition?

Ekuba is not a systemic antibiotic but is classified as a synthetic chemical antiseptic and germicide. A key property that differentiates it from many other oral hygiene products is its high 'substantivity,' which allows it to bind to tissues and maintain a continuous, protective anti-microbial effect on the application surface.


Q: Does Ekuba change how other medications are absorbed?

Official drug information confirms that only minimal amounts of the active ingredient are absorbed into the body after use. This minimal systemic absorption means Ekuba is not expected to interfere with the absorption or exposure of other systemic medications.


Q: Is Ekuba considered a long-term treatment option?

The oral rinse is officially indicated for the treatment of gingivitis as part of a professional care program. Official safety notes caution that prolonged use may lead to reversible staining. Use is often characterized as short-term or intermittent, depending on the condition being addressed.


Q: What should I do if I forget to take a dose of Ekuba?

Official patient information states that a missed dose may be taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose should generally be skipped to return to the normal routine. It is not recommended to use a double dose to compensate for a missed one.


Q: Do I need to avoid any specific foods while taking Ekuba?

The most important instruction is to avoid consuming any food or beverages immediately after using the oral rinse. Official labeling does not contain instructions to avoid any specific food or food type throughout the entire course of treatment.


Q: Is there a generic version of Ekuba available?

Yes, Ekuba is a brand name, and the active ingredient, Chlorhexidine Gluconate, is widely available under various generic labels in the 0.12% oral rinse strength and as topical solutions.


Q: How does the body process Ekuba?

Following topical or oral rinse use, the majority of the drug remains bound to the tissue at the application site for local action. Only minimal amounts are absorbed into the body, and these small amounts are generally eliminated rapidly, mostly through the feces.


Q: Can Ekuba affect my ability to drive or operate machinery?

Due to its minimal systemic absorption, Ekuba is not known to cause central nervous system (CNS) side effects. As CNS effects are not listed among the documented side effects, the drug is not generally expected to affect the ability to drive or operate machinery.


Q: What happens if I suddenly stop taking Ekuba?

As a topical antiseptic that is minimally absorbed, Ekuba is not associated with systemic withdrawal or 'rebound' symptoms. Stopping treatment simply ends the localized anti-microbial activity and sustained anti-plaque action.


Q: Is Ekuba commonly prescribed outside of the United States?

Yes, the active ingredient, Chlorhexidine Gluconate, is approved and widely recognized by government regulatory bodies in numerous countries around the world, including those in Europe, the UK, and Canada, and is a globally utilized antiseptic agent.


Q: Does Ekuba have a high risk of drug dependency?

No, Ekuba is not classified as a controlled substance by any regulatory agency. Due to its mechanism as a local antiseptic and its minimal systemic absorption, it is not associated with any known risk of drug dependency or abuse potential.


Q: Is it possible to be allergic to Ekuba?

Yes, the product is formally contraindicated for use in any person with a known history of hypersensitivity or allergy to the active ingredient, Chlorhexidine Gluconate. Regulatory agencies have reported rare but serious systemic hypersensitivity reactions, including anaphylaxis.


Q: How long does Ekuba stay in your system after stopping treatment?

The active ingredient that is systemically absorbed is eliminated rapidly, primarily through the feces. While the local binding (substantivity) provides a residual effect on the applied surface, the elimination of the small absorbed amount from the body is generally quick.


Q: Are there different versions or strengths of Ekuba?

Yes, Ekuba is available in multiple distinct regulatory forms. These include a 0.12% oral rinse, a 4% topical solution for external skin use, and a 2.5 mg periodontal chip, each intended for a specific application route and purpose.


Q: Do any herbal products or vitamins interact with Ekuba?

Official drug labels indicate no known systemic interactions with other substances due to minimal absorption. However, some health sources advise caution because there is often insufficient regulatory data to guarantee the safety of using complementary medicines, herbal remedies, or supplements with chlorhexidine.


Q: Why do some people say Ekuba did not work for them?

Efficacy can vary widely between different individuals. Official research notes indicate that evidence quality varies across studies, and findings for certain patient subgroups may be uncertain. Furthermore, the local effect can be compromised by poor adherence, such as using certain toothpastes or immediately rinsing with water after use.


Q: Is Ekuba a type of biologic medicine?

No, Ekuba is a commercial trade name for the active ingredient, Chlorhexidine Gluconate. This is classified by regulatory authorities as a synthetic chemical entity belonging to the bisbiguanide class, not a biologic medicine derived from biological sources.


Q: Are the benefits of Ekuba permanent after the treatment stops?

The benefits are tied to the drug's continuous local anti-microbial action, and research evidence focuses on short-term and medium-term effects during use. The benefits are not documented by regulatory sources as a permanent cure for the underlying condition after treatment was stopped.


Q: Is Ekuba suitable for people with heart conditions?

Official labeling does not list heart conditions as a contraindication or population-specific warning for the approved oral rinse or topical uses. This is consistent with the drug's mechanism of minimal systemic absorption, which limits internal effects on major organs.


Q: Can I use Ekuba if I have an autoimmune condition?

Regulatory labeling does not list autoimmune conditions as a contraindication or population-specific warning for the approved oral rinse or topical uses. Contraindications are limited to a known history of hypersensitivity to the drug and use on specific anatomical sites.

How should Ekuba be stored and disposed of?

Ekuba (Chlorhexidine Gluconate) must be stored and disposed of according to strict official guidelines to maintain product integrity and safety.

Storage Requirements

Ekuba must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and kept in a closed, tightly sealed container. It is mandatory to keep from freezing and to avoid excessive heat. For safety, the medicine must be stored out of the reach of children.

Disposal Instructions

Unused or expired Ekuba must be discarded in accordance with all applicable local, regional, and national regulations for pharmaceutical waste. Disposal instructions explicitly state to avoid release to the environment, including preventing runoff into soil, waterways, drains, and sewers. Do not keep outdated medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ekuba found in:

A-Z Index: